MOB — Moberg Pharma AB (publ) Share Price
- SEK643.11m
- SEK587.30m
- 21
- 42
- 93
- 49
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 1.05 | ||
Price to Tang. Book | 8.19 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | n/a | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -4.47% | ||
Return on Equity | -3.69% | ||
Operating Margin | n/a |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | SEKm | 15.55 | 50.49 | n/a | 0.21 | n/a | 5 | 42 | -100% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.
Directors
- Peter Wolpert CHM (51)
- Anna Ljung CEO (42)
- Mark Beveridge VFN (42)
- Agneta Larhed VPR
- Annica Magnusson OTH (57)
- Cindy Wong OTH (61)
- Fredrik Granstrom IND (52)
- Andrew Hochman IND (42)
- Mattias Klintemar IND (54)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 31st, 2006
- Public Since
- May 26th, 2011
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 27,961,478
- Address
- Gustavslundsvagen 42, 5 tr., BROMMA, 167 51
- Web
- https://www.mobergpharma.se/
- Phone
- +46 852230700
- Auditors
- Ernst & Young AB
Upcoming Events for MOB
Moberg Pharma AB (publ) Annual Shareholders Meeting
Q2 2024 Moberg Pharma AB (publ) Earnings Release
Similar to MOB
Biogaia AB
OMX Nordic Exchange Stockholm
BoneSupport Holding AB
OMX Nordic Exchange Stockholm
Calliditas Therapeutics AB
OMX Nordic Exchange Stockholm
Camurus AB
OMX Nordic Exchange Stockholm
Cline Scientific AB
OMX Nordic Exchange Stockholm
FAQ
As of Today at 18:14 UTC, shares in Moberg Pharma AB (publ) are trading at SEK23.00. This share price information is delayed by 15 minutes.
Shares in Moberg Pharma AB (publ) last closed at SEK23.00 and the price had moved by +26.14% over the past 365 days. In terms of relative price strength the Moberg Pharma AB (publ) share price has outperformed the FTSE Global All Cap Index by +8.79% over the past year.
The overall consensus recommendation for Moberg Pharma AB (publ) is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Moberg Pharma AB (publ) does not currently pay a dividend.
Moberg Pharma AB (publ) does not currently pay a dividend.
Moberg Pharma AB (publ) does not currently pay a dividend.
To buy shares in Moberg Pharma AB (publ) you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of SEK23.00, shares in Moberg Pharma AB (publ) had a market capitalisation of SEK643.11m.
Here are the trading details for Moberg Pharma AB (publ):
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: MOB
Based on an overall assessment of its quality, value and momentum Moberg Pharma AB (publ) is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Moberg Pharma AB (publ). Over the past six months, its share price has outperformed the FTSE Global All Cap Index by +192.4%.
As of the last closing price of SEK23.00, shares in Moberg Pharma AB (publ) were trading +110.02% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Moberg Pharma AB (publ) PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK23.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Moberg Pharma AB (publ)'s management team is headed by:
- Peter Wolpert - CHM
- Anna Ljung - CEO
- Mark Beveridge - VFN
- Agneta Larhed - VPR
- Annica Magnusson - OTH
- Cindy Wong - OTH
- Fredrik Granstrom - IND
- Andrew Hochman - IND
- Mattias Klintemar - IND